written on 06.03.2014

Market Insight: PCSK9 Inhibitors – The Race to Become the Next New Cholesterol Block Buster


Ulrike Jahnke, Editor at Thomson Reuters, reviews the race between several pharmaceutical companies to launch the first-to-market PCSK9 inhibitor, a new class of drugs hailed the most important new heart medicines in years, with resulting multibillion-dollar sales potential. Cardiovascular disease (CVD) remains the number one killer worldwide and an estimated 23.3 million people globally will […]